Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder

J Cereb Blood Flow Metab. 2020 Mar;40(3):552-562. doi: 10.1177/0271678X19828916. Epub 2019 Feb 10.

Abstract

Striatal dopamine transporter (DAT) deficiency and abnormal expression of Parkinson's disease (PD)-related pattern (PDRP) have been observed in patients with idiopathic REM sleep behavior disorder (IRBD). This study aimed to investigate the correlations between these two measures with comparison to PD using a dual tracer imaging design. Age-matched 37 IRBD patients, 86 PD patients, and 15 control subjects underwent concurrent PET scans with 11C-CFT to quantify dopaminergic dysfunction and 18F-FDG to quantify PDRP expression. IRBD patients were divided into two subgroups: those with relatively normal (IRBD-RN) or abnormal (IRBD-AB) striatal DAT binding. Significantly decreased DAT binding and increased PDRP scores were present in all patient groups, except for IRBD-RN, relative to the controls. There was a significant effect of hemisphere and hemisphere × group interaction for DAT binding but not for PDRP expression. Significant correlations were observed between DAT binding and PDRP expression in the IRBD-AB and PD groups but not in the IRBD-RN group. IRBD patients present with an intermediate state in striatal DAT distribution and PDRP activity between PD and normal controls. The modest correlations between the two measures in both IRBD and PD suggest that differences in network activity cannot be fully explained by nigrostriatal dopaminergic denervation.

Keywords: Dopamine transporter; Parkinson's disease; metabolic brain network; positron emission tomography; rapid-eye-movement sleep behavior disorder.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Corpus Striatum* / diagnostic imaging
  • Corpus Striatum* / metabolism
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / deficiency
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / metabolism
  • Positron-Emission Tomography*
  • REM Sleep Behavior Disorder* / diagnostic imaging
  • REM Sleep Behavior Disorder* / metabolism
  • Tropanes / administration & dosage

Substances

  • 2beta-carbomethoxy-3beta-(4-(11C)fluorophenyl)tropane
  • Dopamine Plasma Membrane Transport Proteins
  • Tropanes
  • Fluorodeoxyglucose F18
  • Dopamine